/ 74 items

#NVO↓

Featured/ LLY/ 08/01/2025 · 10:51 AM

Trump Admin Eyes Major GLP-1 Weight Loss Drug Coverage

The Trump administration is considering a five-year pilot program for Medicare & Medicaid to cover costly GLP-1 weight-loss drugs like Wegovy & Zepbound for millions, a significant policy shift.

Featured/ NVO/ 07/29/2025 · 10:03 AM

Novo Nordisk Lowers 2025 Outlook, Names New CEO

Novo Nordisk cut its 2025 sales and profit forecast due to slower US Wegovy & Ozempic sales, hit by competition and compounded GLP-1s. Maziar Mike Doustdar is the new CEO.